Shares of Metsera, Inc. (NASDAQ:MTSR - Get Free Report) fell 12.6% on Wednesday . The stock traded as low as $12.40 and last traded at $12.42. 285,175 shares changed hands during trading, a decline of 62% from the average session volume of 747,144 shares. The stock had previously closed at $14.21.
Wall Street Analyst Weigh In
MTSR has been the topic of a number of recent analyst reports. Guggenheim began coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price target on the stock. Cantor Fitzgerald began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating for the company. Finally, Evercore ISI began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating on the stock.
Check Out Our Latest Report on Metsera
Metsera Price Performance
The stock has a fifty day moving average price of $25.74.
Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
